欢迎访问《现代生物医学进展》编辑部！

肝癌是世界范围内恶性程度最高的恶性肿瘤之一。门静脉癌栓的出现加速了肝功衰竭以及门静脉高压的发生概率，严重影响了肝癌患者的预后，临床上对于肝癌合并门静脉癌栓的诊疗尤为棘手。传统的治疗手段对于肝癌合并门静脉癌栓的疗效欠佳，且创伤大、住院时间长、并发症多。介入治疗因其创伤小、住院时间短、并发症少，疗效确切等优势逐渐被人们认可。以往单独应用经导管肝动脉化疗栓塞术（ Transcatheter Arterial Chemoembolization, TACE）治疗肝癌取得了可喜的成果，随着介入治疗的发展， TACE 联合其他介入手段治疗肝癌伴门静脉癌栓引起了越来越多的学者重视。本文回顾了近几年来国内外的相关文献，对 TACE 联合其他介入手段治疗肝癌合并门静脉癌栓的方式及疗效做一综述，以期对肝癌的临床诊疗工作提供一些帮助。

英文摘要:

Hepatocellular carcinoma is the one of the most malignant tumor worldwide, Portal vein tumor thrombus appears to accelerate the probability of hepatocellular carcinoma failure and portal hypertension. Portal vein tumor thrombus has a serious impact on the prognosis of patients with liver cancer. It is difficult to diagnosis and treatment for hepatocellular carcinoma with portal vein tumor thrombus. The traditional method to treat hepatocellular carcinoma with portal vein tumor thrombus is poor with the trauma, long hospital stay and complications. as result of small trauma ,shorter hospital stay, fewer complications and efficacy has gradually recognized by the people. In the past, some encouraging results has been achieved by transcatheter arterial chemoembolization along for treatment of hepatocellular carcinoma with portal vein tumor thrombus. In recent years， with the development of interventional treatment, more and more attention are paid on the TACE combined with other means of intervention in the treatment of hepatocellular carcinoma with portal vein tumor thrombus. This paper reviews the literature at home and abroad in recent years, and achieved a review about the TACE combined with other means of interventional therapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus， in order to provide some help to the diagnosis and treatment of hepatocellular carcinoma.

查看全文查看/发表评论下载PDF阅读器

关闭